In the present study, we demonstrated that the administration of DPP4i ameliorated the pathogenesis of NASH in the AMLN diet-induced mouse model, suppressed lipoapoptosis, and downregulated hepatic DPP4 expression. The gene discussed is DPP4; the disease is metabolic dysfunction-associated steatohepatitis.